The new drug combinations:: their place in the treatment of uncomplicated Plasmodium falciparum malaria
The new drug combinations:: their place in the treatment of uncomplicated Plasmodium falciparum malaria
复制标题
DOI：
10.1046/j.1472-8206.2003.00165.x
复制
发表时间：
2003-04-01
影响因子：
2.9
通讯作者：
Bricaire, F
中科院分区：
文献类型：
--
作者：
Danis, M;Bricaire, F
疟疾是发展中国家发病率和死亡率的主要原因。在药物压力下选择突变的恶性疟原虫疟疾菌株导致了抗药性的发展。目前迫切需要有效、安全、实用的药物组合，具有较低的选择压力。对最近注册或仍在开发的多种药物组合进行了审查，特别关注阿托伐醌-氯胍和蒿甲醚-苯芴醇组合。
Malaria is a leading cause of morbidity and mortality in developing countries. Selection of mutant Plasmodium falciparum malaria strains under drug pressure has led to the development of drug resistance. There is a pressing need for effective, safe, practicable drug combinations that have lower selection pressure. A review of the mein drug combinations, which arc recently registered or are still under development, was undertaken, with special attention to the atovaquone-proguanil and artemether-lumefantrine combination.